EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Efficacy and safety of intranasal bencycloquidium bromide in nasal symptoms of common cold: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Lixiu He, Ling Yang, Haiying Yan, Yousheng Chen, Yuanyuan Liu, Chengling Zhao, Dang Lin, Fang Zhang, Maofeng Liu, Qiong Tang, Nali Zhang, Wenjun Li und 6 weitere

QJM: An International Journal of Medicine · 2025

DOI: 10.1093/qjmed/hcaf331 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift QJM: An International Journal of Medicine, 2025. Verfasst von Lixiu He und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Common Cold, Rhinorrhea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Yingu Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Common cold is one of the most prevalent illnesses affecting human health. Nasal symptoms are the most bothersome and characteristic manifestations, yet few safe and effective treatments are currently available.

Aim

This phase 3, randomized, double-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of bencycloquidium bromide (BCQB) nasal spray in nasal symptoms of common cold.

Methods

Participants with cold symptoms for ≤48 h and a rhinorrhea visual analogue scale (VAS) score ≥5 were enrolled. Participants were randomized 1:1 to receive either BCQB or placebo for 4 ± 1 days. Patients self-recorded VAS scores for rhinorrhea, sneezing, nasal congestion and itching daily. Efficacy and safety were assessed.

Results

A total of 480 patients were randomized and treated. The area under the curve (AUC) for rhinorrhea VAS scores over treatment period was significantly lower in the BCQB group than in the placebo group (13.01 ± 7.19 vs. 16.01 ± 8.00; P < 0.001). Daily improvement in the average rhinorrhea VAS score was significantly greater in the BCQB group from day 2 through day 4 (P < 0.005). BCQB also demonstrated significant efficacy for nasal congestion (AUC: 10.90 ± 7.42 vs. 13.63 ± 8.64; P < 0.001) and sneezing (AUC: 7.84 ± 7.18 vs. 9.30 ± 8.64; P = 0.046). The incidence of adverse events (AEs) was similar between the two groups, and no severe AEs were reported. BCQB was well-tolerated, with no systemic anticholinergic adverse effects observed.

Conclusions

BCQB nasal spray is effective and safe for treating rhinorrhea, nasal congestion and sneezing associated with common cold.

Trial registration

The trial was registered at chictr.org.cn (ChiCTR2500107341).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Common ColdRhinorrheaHumansDouble-Blind MethodFemaleMaleMiddle AgedTreatment OutcomeAdultAdministration, IntranasalSneezingYoung AdultNasal SpraysBridged Bicyclo Compounds, Heterocyclic

Substanzen

bencycloquidium bromideNasal SpraysBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Respiratory and Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
  • Department of Respiratory and Critical Care Medicine, Zibo Central Hospital, Zibo, Shandong, China.
  • Clinical Trial Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Department of Respiratory and Critical Care Medicine, Suzhou Municipal Hospital, Suzhou, Jiangsu, China.

ORCID-Profile: Chuntao Liu

Förderung

  • Yingu Pharmaceutical Co., Ltd

Zitieren

APA

He, L., Yang, L., Yan, H., Chen, Y., Liu, Y., Zhao, C., Lin, D., Zhang, F., Liu, M., Tang, Q., Zhang, N., Li, W., Ao, S., Liu, X., Sun, W., Dong, L., Xu, S., & Liu, C. (2025). Efficacy and safety of intranasal bencycloquidium bromide in nasal symptoms of common cold: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. QJM: An International Journal of Medicine. https://doi.org/10.1093/qjmed/hcaf331

Vancouver

He L, Yang L, Yan H, Chen Y, Liu Y, Zhao C, et al. Efficacy and safety of intranasal bencycloquidium bromide in nasal symptoms of common cold: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. QJM: An International Journal of Medicine. 2025. doi:10.1093/qjmed/hcaf331

BibTeX
@article{He2025,
  author = {He, Lixiu and Yang, Ling and Yan, Haiying and Chen, Yousheng and Liu, Yuanyuan and Zhao, Chengling and Lin, Dang and Zhang, Fang and Liu, Maofeng and Tang, Qiong and Zhang, Nali and Li, Wenjun and Ao, Suhua and Liu, Xunchao and Sun, Wuzhuang and Dong, Liang and Xu, Shufeng and Liu, Chuntao},
  title = {Efficacy and safety of intranasal bencycloquidium bromide in nasal symptoms of common cold: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial},
  journal = {QJM: An International Journal of Medicine},
  year = {2025},
  doi = {10.1093/qjmed/hcaf331}
}
Kostenlos starten →